Abstract
This study was conducted to evaluate the efficacy and the tolerability of a four-drug chemotherapy regimen combined with interferon α(IFN) in metastatic melanoma. Between March 1991 and August 1993, 55 patients with advanced melanoma were enrolled for the present multicentre phase II study. Fortynine patients were eligible and evaluable for toxicity; 48 patients were evaluable for response. The treatment schedule consisted of a 5-day regimen of dacarbazine, vincristine, bleomycin and lomustine, plus 6×106 IU IFNα three times weekly subcutaneously for 2 weeks starting on day 8. The cycle was repeated on day 29. Among the 48 assessable patients, 16 objective responses were seen, yielding a response rate of 33% (95% confidence interval 20%–46%). Seven patients achieved a complete response (CR) of a median of 6 + months (range 1 + to 21 + months) and 9 patients achieved a partial response (PR) of a median of 9 months (range 4–13 months). The median overall survival was 12 + months (range 6+ to 23 + months) for the patients with CR and 15 + months (range 8–20 months) for the patients with PR. Even the survival of the 7 patients with stable disease was fairly long (median 12, range 7–17 months), appearing to be significantly longer than the survival of the 25 patients with progressive disease (median 5, range 1–24 + months). The treatment was moderately well tolerated, although all patients experienced some mild form of toxicity, mostly gastrointestinal symptoms, neurotoxicity and haematotoxicity. Grade 3–4 adverse effects were noted in 39% of the patients. No toxic deaths occurred. It can be concluded that the present regimen produces meaningful responses for patients with metastatic melanoma. A randomised study is needed to determine the effect on survival.
Similar content being viewed by others
Abbreviations
- IFN :
-
interferon
- DOBC :
-
dacarbazine, vincristine, bleomycin, lomustine
References
Aapro MS (1993) Advances in systemic treatment of malignant melanoma. Eur J Cancer 29A/613–617
Buzaid AC, Murren J (1992) Chemotherapy for advanced malignant melanoma. Int J Clin Lab Res 21:205–209
Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, Buzzi F, Ceci G, Corgna E, Costa P, Lottici R, Papadia F, Sofra MC, Bacchi M (1992) Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327:516–523
Dixon WJ (1981) BMDP statistical software. University of California Press, Berkeley Los Angeles London
Falkson CI, Falkson G, Falkson HC (1991) Improved results with the addition of interferon alfa-2b dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403–1408
Gröhn P, Kumpulainen E, Nuortio L, Hakala T, Vuoristo MS, Korpela M, Heikkinen M, Salmi R, Jakobsson M, Numminen S (1992) A phase II study of metastatic melanoma treated with a combination of interferon alfa-2b, dacarbazine and nimustine. Eur J Cancer 28:441–443
Hoon DSB, Hayashi Y, Morisaki T, Foshag LJ, Morton DL (1993) Interleukin-4 plus tumor necrosis factor alfa augments the antigenicity of melanoma cells. Cancer Immunol Immunother 37:378–384
Kellokumpu-Lehtinen P, Nordman E (1988) Combined interferon and vinblastine treatment of advanced melanoma and renal cell cancer. Cancer Detect Prev 12:523–529
Kirkwood JM (1991) Studies of interferons in the therapy of melanoma. Semin Oncol 18 [Suppl 7]:83–90
Legha SS (1989) Current therapy for malignant melanoma. Semin Oncol 16 [Suppl 1]:34–44
Legha SS, Buzaid AC (1993) Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol 20 [Suppl 9]:27–32
Legha SS, Papadopoulos NEJ Plager C, Ring S, Chawla SP, Evans LM, Benjamin RS (1987) Clinical evaluation of recombinant interferon alfa-2A (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 5:1240–1246
Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R (1989) A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine and dacarbazine (CDV) for metastatic melanoma. Cancer 64:2024–2029
McClay EF, Mastrangelo MJ (1988) Systemic chemotherapy for metastatic melanoma. Semin Oncol 15:569–577
McLeod GRC, Thomson DB, Hersey P (1987) Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I–II study in combination with DTIC. Int J Cancer Suppl 1:31–35
Merimsky O, Inbar M, Reider-Groswasser I, Chaitchik S (1992) Brain metastases of malignant melanoma in interferoron complete responders: clinical and radiological observations. J Neurooncol 12:137–40
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214
Mitchell MS, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell WD, Groshen S (1994) Increased effectiveness of interferon alfa-2B following active specific immunotherapy for melanoma. J Clin Oncol 12:402–411
Price CG, Rohatiner AZS, Steward W, Deakin D, Bailey N, Norton A, Blackledge G, Crowther D, Lister TA (1991) Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: preliminary results of a randomized trial in progress. Eur J Cancer 27 [Suppl 4]:34–36
Pyrhönen S, Hahka-Kemppinen M, Muhonen T (1992) A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 10:1919–1926
Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180–199
Schiller JH, Hawkins MJ, O'Connell MJ, Sielaff K, Borden EC (1989) A phase I trial of interferon-alfa-2a plus cyclophosphamide, vincristine, prednisone and doxorubicin. J Biol Response Mod 8:252–261
Sertoli MR, Queirolo P, Bajetta E, Negretti E, Calabresi F, Barduagni L, Giannotti B, Brogelli L, Bernengo MG, Sofra MC, Maifredi G, Zumiani G, Comella G, Bruzzoni R, DiLeo A, Criscuolo D, Fawst C, Cascinelli N (1992) Dacarbazine (DTIC) with or without recombinant interferon alfa-2a at different dosages in the treatment of stage IV melanoma patients. Preliminary results of a randomized trial. Proc Am Soc Clin Oncol 11:345
Smith KA, Green JA, Eccles JM (1992) Interferon alpha-2a and vindesine in the treatment of advanced malignant melanoma. Eur J Cancer 28:438–441
Thomson D, Adena M, McLeod GRC, Hersey P, Gill P, Coates A, Olver I, Kefford R, Lowenthal R, Beadle G, Walpole E, Boland K, Kingston D (1992) Interferon alfa-2a (IFN) does not improve response or survival when added to dacarbazine (DTIC) in metastatic melanoma. Results of a multi-institutional Australian randomized trial QMP8704. Proc Am Soc Clin Oncol 11:343
Vuoristo MS, Gröhn P, Kumpulainen E, Korpela M (1994) Treatment of patients with metastatic melanoma with a one-day regimen of dacarbazine, vincristine, bleomycin and lomustine plus alfa-interferon. Eur J Cancer 30A:420
Zignego AL, Barbagli S, Mazzanti R, Foschi M, Rossi S, Laffi G, Buzzelli G, Gentilini P (1991) Therapy of chronic active hepatitis C with alfa-interferon: effectiveness and prognostic factors. In: Gentilini P, Dianzani MU (eds) Experimental and Clinical Hepatology. Excerpta Medica, Amsterdam, pp 253–259.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vuoristo, MS., Gröhn, P., Kellokumpu-Lehtinen, P. et al. Intermittent interferon and polychemotherapy in metastatic melanoma. J Cancer Res Clin Oncol 121, 175–180 (1995). https://doi.org/10.1007/BF01198100
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01198100